BioCentury This Week Ep. 200 - Merck-Daiichi, Roche-Roivant, Base Editors
Oct 24, 2023
Merck & Co. in-licenses three Antibody Drug Conjugates (ADCs) from Daiichi Sankyo in a $4 billion deal. The podcast also discusses Roche's $7.1 billion deal for Roivant Sciences' Telavant subsidiary and the expanding therapeutic potential of base editors in gene editing.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 2min
Merck and Daiichi's $22 Billion Biotech Licensing Deal
02:16 • 4min
Comparison of HER-2 and TROP 2 in Cancer Treatment
05:52 • 12min
Exploring the Therapeutic Potential of Base Editors in Gene Editing
18:10 • 2min
Progress and Potential of Base Editing Techniques
20:32 • 4min
Discussion on beam therapeutics, cost-cutting, and prioritization in genetic diseases research
25:01 • 3min